Background: Chemokine (C-X-C motif) ligand (CXCL)9 and CXCL11 play an important role in the initial phases of autoimmune thyroiditis (AT); however their serum levels in patients with Graves'disease (GD) have never been evaluated in relation to thyroid function and treatment. Methods: To evaluate CXCL9 and CXCL11 serum levels in GD, to relate these parameters to the clinical phenotype, we measured CXCL9 and CXCL11 serum levels in 91 GD patients, 91 AT, 34 non-toxic multinodular goiters (MNG), 31 toxic nodular goiters (TNG) and 91 healthy controls (age- and sex-matched). Results: Mean CXCL9, or CXCL11, levels were higher in GD, in comparison with controls, or euthyroid AT, or MNG, or TNG (*p < 0.05, ANOVA; CXCL9: 274±265, *76±33, *132±78, *87±48, *112±56 pg/mL; CXCL11: 140±92, *64±20, 108±48, *76±33, *91±41 pg/mL; respectively). Hyperthyroid GD had significantly higher CXCL9 or CXCL11 than euthyroid or hypothyroid GD. GD with untreated hyperthyroidism had higher CXCL9 or CXCL11 than hyperthyroid or euthyroid GD under methimazole (MMI) treatment. Comparable CXCL9 and CXCL11 levels were observed in newly diagnosed untreated hyperthyroid GD vs. untreated patients with relapse of hyperthyroidism after a previous MMI course. Conclusions: Serum CXCL9, and CXCL11, levels are associated with the active phase of GD both in newly diagnosed and relapsing hyperthyroid patients. The reduction of serum CXCL9 and CXCL11 levels in treated patients with GD may be related to the immunomodulatory effects of MMI.

Increase of interferon-γ inducible α chemokine (C-X-C motif) ligand (CXCL)9 and CXCL11 serum levels in patients with active Graves' disease, and modulation by methimazole therapy.

ANTONELLI, ALESSANDRO;Ferrari SM;FERRANNINI, ELEUTERIO;Fallahi P.
2013

Abstract

Background: Chemokine (C-X-C motif) ligand (CXCL)9 and CXCL11 play an important role in the initial phases of autoimmune thyroiditis (AT); however their serum levels in patients with Graves'disease (GD) have never been evaluated in relation to thyroid function and treatment. Methods: To evaluate CXCL9 and CXCL11 serum levels in GD, to relate these parameters to the clinical phenotype, we measured CXCL9 and CXCL11 serum levels in 91 GD patients, 91 AT, 34 non-toxic multinodular goiters (MNG), 31 toxic nodular goiters (TNG) and 91 healthy controls (age- and sex-matched). Results: Mean CXCL9, or CXCL11, levels were higher in GD, in comparison with controls, or euthyroid AT, or MNG, or TNG (*p < 0.05, ANOVA; CXCL9: 274±265, *76±33, *132±78, *87±48, *112±56 pg/mL; CXCL11: 140±92, *64±20, 108±48, *76±33, *91±41 pg/mL; respectively). Hyperthyroid GD had significantly higher CXCL9 or CXCL11 than euthyroid or hypothyroid GD. GD with untreated hyperthyroidism had higher CXCL9 or CXCL11 than hyperthyroid or euthyroid GD under methimazole (MMI) treatment. Comparable CXCL9 and CXCL11 levels were observed in newly diagnosed untreated hyperthyroid GD vs. untreated patients with relapse of hyperthyroidism after a previous MMI course. Conclusions: Serum CXCL9, and CXCL11, levels are associated with the active phase of GD both in newly diagnosed and relapsing hyperthyroid patients. The reduction of serum CXCL9 and CXCL11 levels in treated patients with GD may be related to the immunomodulatory effects of MMI.
Antonelli, Alessandro; Ferrari, Sm; Corrado, A; Ferrannini, Eleuterio; Fallahi, P.
File in questo prodotto:
File Dimensione Formato  
Thyroid 2013.pdf

solo utenti autorizzati

Tipologia: Versione finale editoriale
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 512 kB
Formato Adobe PDF
512 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Thyroid 2013.pdf

accesso aperto

Tipologia: Documento in Post-print
Licenza: Tutti i diritti riservati (All rights reserved)
Dimensione 388.69 kB
Formato Adobe PDF
388.69 kB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/224931
Citazioni
  • ???jsp.display-item.citation.pmc??? 11
  • Scopus 37
  • ???jsp.display-item.citation.isi??? 18
social impact